Sorry, nothing found.
CEO at Deerfield Catalyst
Dr. Levin is a Heart Failure Cardiologist by training and a veteran in the field of biomedical engineering and cardiology.
As co-founder of Coridea, his inventions and co-inventions have successfully launched companies including Ardian (Medtronic), CHF Solutions (Gambro), Respicardia (formerly, Cardiac Concepts), eValve (Abbott) and RenalGuard/Reprieve Cardiovascular (PLC Medical), Cibiem and Soffio Medical. He has held a number of positions in these companies including President, Chief Scientific Officer, Chief Medical Officer and VP of R&D.
President & Chief Executive Officer
Chad has more than two decades of experience bringing innovative medical technologies to market. He previously served as General Manager of Home and Vice President of Strategy for Outset Medical, a rapidly growing player in the dialysis market, where he developed the initial commercialization strategy and supported several rounds of fundraising, including a successful IPO. Prior to Outset, Chad was Division Vice President of Heart Failure Therapies at Abbott where he was responsible for global marketing of the Mechanical Circulatory Support (formerly Thoratec) and CardioMEMS franchises. Before Abbott, he was with McKinsey & Company, a consulting firm where he served clients in both medtech and biotech industries as well as several early-stage healthcare companies. He holds a bachelor’s degree in Economics from Georgetown University, a master’s degree in Public Health from Columbia University and a master’s degree in Business Administration from The Wharton School of Business at the University of Pennsylvania.
Independent Board Member
Brian Farley is a retired medical device executive and entrepreneur who built multiple successful medical technology companies from early-stage technology development, through commercialization and scaleup. He was CEO of Entellus Medical, and CEO of VNUS Medical Technologies, as well as board chair of Neuronetics Inc, all publicly traded companies. Mr. Farley led Entellus and VNUS from early stages through successful IPOs, and served on the Entellus and VNUS boards until the acquisition of each company. Mr. Farley was also Board Chair of Myoscience Inc. when it was acquired. Prior to joining VNUS, Mr. Farley served in various management and executive positions in R&D, clinical research, and business development at the Vascular Intervention Division of Guidant Corporation and in the Medical Device Division of Eli Lilly and Company. Mr. Farley has served on the Boards of over 10 medtech companies and non-profits. Mr. Farley earned his bachelor’s degree in engineering with an emphasis in biomedical engineering and his Master’s Degree in electrical engineering from Purdue University.
Partner at Action Potential Venture Capital
Imran Eba is a founding partner at Action Potential Venture Capital, GSK’s corporate venture capital fund focused on investing in companies that pioneer bioelectronic medicines and other whitespace non-drug therapies. Imran represents Action Potential as a board member at Axon Therapies and a number of other portfolio companies. Imran is also a founding member and program advisor to the Harvard Healthtech Fellowship, on the Board of Trustees at the Hartford International University for and on the Board of Ambassadors of the Brooke Charter School a K-12 public charter school network in Boston. Imran is based in Cambridge, MA.
Partner at Deerfield Management
David Neustaedter, Ph.D., is a Venture Partner on the Medical Technologies team and joined the Firm in 2022. Prior to Deerfield, Dr. Neustaedter spent seven years as a Vice President, at Medtronic Ventures and, before Medtronic’s merger with Covidien, spent a further 7 years with Covidien including five years as a Vice President of Venture Capital. He has also held positions at Stryker Development, Leerink Swann/MEDACorp Strategy Consulting, Fletcher Spaght, and Braun Consulting. Dr. Neustaedter holds a B.Sc. in Cellular, Molecular, and Microbial Biology from University of Calgary, an M.B.A from Yale University, and a Ph.D. in Molecular Biology from University of British Columbia
Partner at Deerfield Management
Andrew ElBardissi, M.D., is a Partner on the Medical Technologies team and joined the Firm in 2017. Prior to Deerfield, Dr. ElBardissi was a Principal at Longitude Capital, where he focused on investments in medtech and biotechnology. Before that, he was an Associate in JPMorgan’s healthcare investment banking practice. Dr. ElBardissi received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. He has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has authored over 30 publications in leading peer-reviewed scientific journals and has presented his research at numerous medical and surgical conferences. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.
Mt. Sinai
Vivek Y. Reddy, MD is Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai.
Dr. Reddy is a leading electrophysiologist, who focuses on developing and testing advanced therapies for cardiac arrhythmias and other conditions – including atrial fibrillation and ventricular tachycardias. He is the lead investigator on several multinational clinical trials exploring new arrhythmia procedures and technologies.
Medical University of South Carolina
Dr. Sheldon E. Litwin is the Alicia Spaulding-Paolozzi Professor of Cardiology and Director of Cardiac Imaging at the Medical University of South Carolina.
Dr. Litwin is nationally recognized for his expertise in advanced cardiac imaging and its use in the diagnosis of heart disease and treatment of patients with heart disease. He has been involved in multiple clinical trials using new therapies for heart failure with preserved ejection fraction (HFpEF).
Mayo Clinic
Dr. Borlaug is Professor of Medicine and Director, Circulatory Failure Research for the Division of Cardiovascular Diseases, and Chair for Research for the Division of Circulatory Failure in the Department of Cardiovascular Medicine at the Mayo Clinic, Rochester, Minnesota.
Dr. Borlaug’s research interests focus on the pathophysiology, diagnosis and treatment of heart failure, particularly heart failure with preserved ejection fraction, with an emphasis on hemodynamics.
Duke University
Dr. Marat Fudim is Assistant Professor of Medicine at Duke University and member of the Duke Clinical Research Institute He currently serves as the Medical Director for the Heart Failure Research Unit and Heart Failure Remote Monitoring.
Dr. Fudim’s research interest is in the pathophysiology of HF, device investigation and neuromodulation. In 2021, he was awarded the Douglas Zipes Distinguished Young Investigator Award for his work in using Splanchnic Nerve Blockade to Manage Heart Failure.
Northwestern University
FAHA, FACC, FASE
Dr. Shah is the Stone Endowed Professor of Medicine and Director of Research for the Bluhm Cardiovascular Institute at Northwestern University Feinberg School of Medicine. Dr. Shah is also Director of the Center for Deep Phenotyping and Precision Therapeutics in the Institute or Augmented Intelligence in Medicine at Northwestern University, and he is Director of the Heart Failure with Preserved Ejection Fraction (HFpEF) Program at Northwestern Memorial Hospital in Chicago, Illinois, USA.
Dr. Shah’s research is focused on improving our understanding of the epidemiology, mechanisms, and treatment of HFpEF. Dr. Shah started the first dedicated HFpEF clinical program in the world at Northwestern University in 2007 and has been a leading enroller in clinical trials for HFpEF since that time.
Senior Clinical Advisor
Dr. Levin is a Heart Failure Cardiologist by training and a veteran in the field of biomedical engineering and cardiology.
As co-founder of Coridea, his inventions and co-inventions have successfully launched companies including Ardian (Medtronic), CHF Solutions (Gambro), Respicardia (formerly, Cardiac Concepts), eValve (Abbott) and RenalGuard/Reprieve Cardiovascular (PLC Medical), Cibiem and Soffio Medical. He has held a number of positions in these companies including President, Chief Scientific Officer, Chief Medical Officer and VP of R&D.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
The Axon™ Ablation System is an investigational device and is not currently approved for clinical use in any geography.
CAUTION – Investigational Device. Limited by Federal (or United States) law to Investigational Use.
ClinicalTrials.gov identifier: NCT04592445
